Dr. Greenfield Invited to Join Englander Institute for Precision Medicine

Dr. Jeffrey Greenfield, Co-Founder of the Children’s Brain Tumor Project, has accepted an invitation to become a standing member of the Weill Cornell Medicine Englander Institute for Precision Medicine. Dr. Greenfield’s formal affiliation with the Institute is in recognition of his work in genomic sequencing of pediatric brain tumors and his ongoing research collaboration with the Institute.

Read More…

The CBTP is proud to be awarded a St Baldrick’s grant for childhood cancer research!

The St. Baldrick’s Foundation, the largest private funder of childhood cancer research grants, has just announced its newest round of grants, and Weill Cornell’s Children’s Brain Tumor Project is proud to be a recipient.  St. Baldrick’s has committed to grant more than $2 million to support the next generation of St. Baldrick’s Fellows and Summer Fellows at 27 institutions across the U.S.

Read more

Lab Update: August 2017

These are exciting times in pediatric neuro-oncology research, and nowhere is that excitement felt more than right here in the CBTP labs. We have recently doubled in size, thanks to the generous support of our families and friends. Where once our two teams worked side by side, taking parallel paths toward our common goal, now we are four. And we couldn’t be happier about that. Read more

On the Horizon: Focused Ultrasound for Brain Tumors?

Dr. Michael Kaplitt, our Vice Chair for Research, made news this summer when he became the first in New York to use Magnetic Resonance-guided Focused Ultrasound (MRgFUS) to treat patients with essential tremor, just a week after the technology received FDA approval. The completely non-invasive technique uses 1,000 low-energy ultrasound waves focused on a precise spot in the brain, each individual wave sparing healthy tissue while the combined energy destroys its target. Read more

Sharing Results of Brain Tumor Research

The Children’s Brain Tumor Project made amazing progress this year, not only in terms of what we learned but also in what we shared. The fact is, getting our discoveries out into the scientific community is just as important as making them in the first place. Research is such an iterative process—we make a small but significant finding and share it by publishing an academic paper read by colleagues around the world, which they then use to advance their own work. They publish their new findings, which we then read and use to inspire our next steps. Back and forth, one step at a time, we move the science forward.

That’s why 2016 was such a big year for us. We made some very interesting findings, but we also concentrated on sharing them. The Internet is a big help here, since it shortens the time it takes to disseminate information. An accepted paper can spend months in the queue for publication, but academic journals now publish electronically in advance of print. That gets our findings into circulation much faster, and it also lets us learn from other labs in a more timely way. Read more

Lab Update: November 2016

There’s an old adage that says if you want to go fast, go alone; if you want to go far, go together. Research science rarely adheres to that—investigators spend a lot of lonely hours peering into microscopes and scrolling through endless data points, all in the hope that someday all that solo work will add up to a breakthrough. We often go alone, and go far, but usually not fast.

The Children’s Brain Tumor Project has also defied that adage in that we are going fast, but together. This requires teamwork like no other—we need other labs at Weill Cornell, tissue banks around the country, and other scientists comparing notes and sharing findings—because we know we need to move quickly, and get far. Read more

Exciting Results from the ”Summer Sprint”

Thanks to a number of grants and private donations, in July and August the CBTP lab team was joined by several young researchers working on specific projects to advance the field of pediatric neuro-oncology. This “summer sprint” was an unprecedented effort that produced some excellent results.

Umberto Tosi, funded by a POST grant from the Alex’s Lemonade Stand Foundation, worked on a project to improve the measurement of drug delivery to the brain via “theranostic” (therapeutic and diagnostic) agents.

The usual method of determining whether a drug has been successfully delivered is to wait for a clinical response, a “wait-and-see” approach that is neither timely nor precise. If researchers could modify a drug to make it fluorescent—and therefore visible on PET or MRI imaging—they would be able to see in real time whether that drug has reached its target. The key is to make delivery of the drug visible and measurable without reducing its effectiveness. Read more